Vaccines

VBI Vaccines to Present at Upcoming Scientific Conferences

Retrieved on: 
Thursday, June 17, 2021
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Medical specialties, Clinical medicine, Health, Vaccines, Infectious causes of cancer, Viral diseases, Virology, Animal virology, Hepatitis, Vaccine, Virus, Coronavirus, Hepatitis B, VBI’s 3-Antigen Hepatitis B Vaccine, VBI Vaccines Inc., HEPATITIS B, VBI’S 3-ANTIGEN HEPATITIS B VACCINE, VBI VACCINES INC.

Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally.

Key Points: 
  • Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally.
  • To learn more about VBIs 3-Antigen Hepatitis B vaccine candidate visit: https://www.vbivaccines.com/sci-b-vac/
    VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.
  • VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM).
  • VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

Newly licensed US manufacturing facility to increase availability of Fluzone® High-Dose Quadrivalent (influenza vaccine)

Retrieved on: 
Thursday, June 17, 2021
Vaccination, Drugs, Vaccines, Medical specialties, Influenza vaccine, Vaccine, Live attenuated influenza vaccine, Sanofi, Influenza, Quadrivalent vaccine, Influenza A virus subtype H3N2

The newly completed facility further expands production and distribution of Sanofi's Fluzone High-Dose Quadrivalent for the upcoming 2021-2022 influenza season in the United States and will create up to 200 additional manufacturing jobs.

Key Points: 
  • The newly completed facility further expands production and distribution of Sanofi's Fluzone High-Dose Quadrivalent for the upcoming 2021-2022 influenza season in the United States and will create up to 200 additional manufacturing jobs.
  • Fluzone High-Dose Quadrivalent is a vaccine indicated for prevention of influenza disease caused by influenza A and B strains contained in the vaccine.
  • Vaccination with Fluzone High-Dose Quadrivalent may not protect all people who receive the vaccine.
  • With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.|

Statement from the Chief Public Health Officer of Canada on June 16, 2021

Retrieved on: 
Wednesday, June 16, 2021
Medical specialties, Medicine, Health, Vaccination, Pediatrics, Vaccine-preventable diseases, Vaccines, Virology, Rubella, Vaccine adverse event, National Advisory Committee on Immunization, Vaccine

The region of the Americas is currently the only World Health Organization (WHO) region to have obtained the elimination status for measles, rubella and CRS.

Key Points: 
  • The region of the Americas is currently the only World Health Organization (WHO) region to have obtained the elimination status for measles, rubella and CRS.
  • At the same time, the Public Health Agency of Canada is providing Canadians with regular updates on COVID-19 vaccines administered , vaccination coverage and ongoing monitoring of vaccine safety across the country.
  • As immunity is still building up across the population, public health measures and individual precautions remaincrucial for COVID-19 control.
  • Working together, Health Canada , the Public Health Agency of Canada , the National Advisory Committee on Immunization , Canada's Chief Medical Officers of Health and other health professionals across the country are closely monitoring vaccine safety , effectiveness and optimal use to adapt approaches.

Global Pneumococcal Vaccine Market (2021 to 2026) - by Type of the Vaccine, Product, Sectors, Distribution Channel and Geography - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 16, 2021
Biotechnology, Pharmaceutical, Health, Medical specialties, Vaccination, Microbiology, Clinical medicine, Pneumonia, Pneumococcal vaccine, Vaccines, Vaccine, Streptococcus pneumoniae, Gavi

The "Global Pneumococcal Vaccine Market (2021-2026) by type of the Vaccine, Product, Sectors, Distribution Channel, Geography, Competitive Analysis and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pneumococcal Vaccine Market (2021-2026) by type of the Vaccine, Product, Sectors, Distribution Channel, Geography, Competitive Analysis and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Global Pneumococcal Vaccine Market is estimated to be USD 8.4 Bn in 2021 and is expected to reach USD 11.8 Bn by 2026, growing at a CAGR of 7%.
  • The factors such as the rising prevalence of pneumococcal diseases amongst the population and the introduction of novel vaccines have supported the growth of the market.
  • The growing awareness programs about pneumococcal diseases initiated by the Government are also boosting the market growth.

Extensive Study in Canada to Assess COVID-19 Vaccine Immune Responses and Effectiveness among People Living With HIV

Retrieved on: 
Wednesday, June 16, 2021
Medical specialties, Health, Medicine, Vaccination, Vaccine, Virology, Vaccines, COVID-19 vaccine, HIV vaccine development, HIV/AIDS

The results of this study will provide critical and timely evidence to inform immunization guidelines and public health strategies for all of the approximately 67,000 Canadians living with HIV.

Key Points: 
  • The results of this study will provide critical and timely evidence to inform immunization guidelines and public health strategies for all of the approximately 67,000 Canadians living with HIV.
  • That data will be compared with the immune reactions from a control group of 100 people who do not have HIV.
  • The second part of the study will look at vaccine effectiveness in people living with HIV compared to people who do not have HIV through a population-based analysis of provincial public health records in Ontario and British Columbia.
  • The Vaccine Surveillance Reference Group (VSRG) supports the monitoring of the safety and effectiveness of COVID-19 vaccines in Canada.

Direct Relief Facilitates Donations of 1.75 Million COVID-19 Vaccine Doses to Mexico, Belize, Bolivia and Paraguay

Retrieved on: 
Tuesday, June 15, 2021
COVID-19 vaccines, Clinical trials, Vaccines, Medicine, RNA vaccines, Health sciences, Medical research, Adenoviridae, FedEx, Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine, COVID-19 vaccine

The deliveries include 1.35 million doses from the U.S. to Mexico and a total of 400,000 doses from Mexico to Belize, Bolivia and Paraguay.

Key Points: 
  • The deliveries include 1.35 million doses from the U.S. to Mexico and a total of 400,000 doses from Mexico to Belize, Bolivia and Paraguay.
  • A FedEx flight arrived today at Toluca International Airport near Mexico City with 1.35 million doses of Johnson & Johnson's single-dose COVID-19 vaccine.
  • The U.S. government sent the vaccine to Mexico with support from Direct Relief, which arranged to fly the doses from the U.S. to Mexico via its longstanding relationship with FedEx.
  • Since January 2020, Direct Relief has provided 38 million doses of temperature-sensitive medication requiring refrigerated shipping to 60 countries.

EDCTP and CEPI Funding Moves IAVI's Lassa fever Vaccine Candidate Into Advanced Clinical Development

Retrieved on: 
Tuesday, June 15, 2021
AIDS, Health, Other Health, General Health, Clinical trials, Research, Science, Medical specialties, Clinical medicine, Medicine, Ebola, Breakthrough therapy, Vaccines, West African Ebola virus epidemic, Lassa fever, Ebola vaccine, rVSV-ZEBOV vaccine, Vaccine, Lassa, Lassa Fever, EDCTP, CEPI, IAVI, LASSA FEVER, EDCTP, CEPI, IAVI

Despite this disease burden, which is believed to be significantly underestimated, no vaccine for Lassa fever is currently available.

Key Points: 
  • Despite this disease burden, which is believed to be significantly underestimated, no vaccine for Lassa fever is currently available.
  • The joint award supports an international collaboration, called Lassa Fever Vaccine Efficacy and Prevention for West Africa (LEAP4WA), to conduct a Phase IIb clinical trial of IAVIs Lassa fever vaccine candidate among adults and children in Liberia, Nigeria, and Sierra Leone.
  • LEAP4WA builds on an existing partnership with CEPI that supports IAVI and a global consortium of partners to conduct Phase I and II clinical trials of IAVIs Lassa fever vaccine candidate.
  • We are excited to apply the recombinant VSV technology, used in the previously licensed Ebola vaccine called ERVEBO, for the development of a much-needed Lassa fever vaccine.

Vaccitech Reports First Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Monday, June 14, 2021
Medicine, Health, Vaccines, Medical research, Vaccitech, Infectious causes of cancer, Papillomavirus, Human papillomavirus infection

OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced financial results for the quarter ended March 31, 2021, and provided an overview of the Companys recent corporate developments.

Key Points: 
  • OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced financial results for the quarter ended March 31, 2021, and provided an overview of the Companys recent corporate developments.
  • The first quarter of 2021 was transformational for Vaccitech as we closed a Series B financing round and initiated patient dosing in our two lead therapeutic programs, HBV and HPV, said Bill Enright, CEO of Vaccitech.
  • Subsequent to the end of the first quarter, the Company closed an initial public offering that raised a gross amount of $110.5 million.
  • Research and development (R&D) expenses: Research and development expenses were $4.6 million for the first quarter of 2021 compared to $4.2 million for the comparable period of the prior year.

Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously

Retrieved on: 
Monday, June 14, 2021
Medical specialties, Vaccination, Drugs, Clinical trials, COVID-19 vaccines, Influenza vaccine, Vaccines, Vaccine efficacy, Vaccine, Novavax COVID-19 vaccine, Novavax, COVID-19 vaccine

In addition, the protection afforded by the candidate vaccine was consistent with the main study at 87.5% and 89.8% respectively.

Key Points: 
  • In addition, the protection afforded by the candidate vaccine was consistent with the main study at 87.5% and 89.8% respectively.
  • All received an approved seasonal influenza vaccine with approximately half the participants co-vaccinated with NVX-CoV2373 while the remainder received placebo.
  • The study demonstrated that vaccine efficacy appeared to be preserved in those receiving both vaccines compared to those vaccinated with NVX-CoV2373 alone.
  • Furthermore, immunogenicity of the influenza vaccine was preserved with concomitant administration while a modest decrease in the immunogenicity of the NVX-CoV2373 vaccine was found.

Seqirus Co-Authors First Study to Assess Simultaneous Administration of Seasonal Influenza Vaccine and COVID-19 Vaccine Candidate

Retrieved on: 
Monday, June 14, 2021
Medical specialties, Vaccination, Health care, Vaccines, Influenza vaccines, Influenza vaccine, Vaccine, CSL Limited, Influenza A virus subtype H1N1, Influenza A virus, Influenza, Live attenuated influenza vaccine

"Seqirus is committed to advancing the science underpinning influenza and taking our place on the front line, alongside our public health partners, as a reliable influenza vaccine supplier."

Key Points: 
  • "Seqirus is committed to advancing the science underpinning influenza and taking our place on the front line, alongside our public health partners, as a reliable influenza vaccine supplier."
  • "As a company on the front line of influenza prevention, we're committed to helping protect our communities with our differentiated portfolio of safe and effective influenza vaccines."
  • Seqirus produces influenza vaccines across its global manufacturing network, which includes facilities in the U.S., U.K. and Australia.
  • As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.